Press release
Geron to Present at the BTIG Virtual Biotechnology Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 12:30 p.m. ET.\n\n\nA live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. If you are unable to listen to the live presentation, an archived webcast will be available on the Company’s website for 30 days.\n\n\nAbout Geron\n\n\nGeron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200804005949/en/\n\nSuzanne Messere\nInvestor and Media Relations\[email protected]\[email protected]\n\nSource: Geron Corporation","length":2502,"tagName":"div"}]